QTORIN rapamycin NDA rolling review, 2H26 filing, 1H27 FDA approval outlook, cash burn & launch plans—read now.
Palvella Therapeutics (NASDAQ:PVLA) said it remains on track to complete its new drug application submission for QTORIN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results